|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.47 USD | -0.81% |
|
+1.08% | +6.26% |
| 03:23pm | BofA Securities Adjusts Bristol-Myers Squibb Price Target to $66 From $67 | MT |
| 01:17pm | Bristol-Myers Squibb Expects Solid Q2 Ahead of Bigger H2, RBC Says | MT |
Insider Transaction History
Latest insider transactions for Bristol-Myers Squibb Company
| Date | Insider | Type | Main position | Quantity | Price | Amount | % Market Cap. | |
|---|---|---|---|---|---|---|---|---|
| 06-29 | Free | Director | 889 | 58.13 | 51.68K | 0.0000% | ||
| 06-29 | Free | Director | 607 | 58.13 | 35.28K | 0.0000% | ||
| 06-29 | Free | Director | 607 | 58.13 | 35.28K | 0.0000% | ||
| 06-29 | Free | Director | 607 | 58.13 | 35.28K | 0.0000% | ||
| 06-29 | Free | Director | 673 | 58.13 | 39.12K | 0.0000% | ||
| 06-14 | Fiscal year | Director | 40,920 | 53.76 | 1.1M | 0.0020% | ||
| 06-02 | Fiscal year | EVP, Corporate Affairs | 19,956 | 17.80 | 212K | 0.0010% | ||
| 04-30 | Fiscal year | Executive/Senior Manager | 3,548 | 16.03 | 34.87K | 0.0002% | ||
| 03-31 | Fiscal year | Chief Operating Officer | 8,306 | 20.89 | 104K | 0.0004% | ||
| 03-31 | Sell | Chief Financial Officer | 30,000 | 61.67 | 1.85M | 0.0015% | ||
| 03-30 | Free | Director | 845 | - | - | 0.0000% | ||
| 03-30 | Free | Director | 639 | - | - | 0.0000% | ||
| 03-30 | Free | Director | 577 | - | - | 0.0000% | ||
| 03-30 | Free | Director | 577 | - | - | 0.0000% | ||
| 03-30 | Free | Director | 577 | - | - | 0.0000% | ||
| 03-09 | Fiscal year | Head of Human Resources | 55,777 | 10.91 | 120K | 0.0027% | ||
| 03-09 | Fiscal year | General Counsel | 84,181 | 10.94 | 130K | 0.0041% | ||
| 03-09 | Free | Chief Technology Officer | 65,306 | - | - | 0.0032% | ||
| 03-09 | Fiscal year | Executive/Senior Manager | 147,150 | 10.18 | 422K | 0.0072% | ||
| 03-09 | Fiscal year | Chief Operating Officer | 122,156 | 10.70 | 467K | 0.0060% | ||
| 03-09 | Fiscal year | President, Cell Therapy Org. | 37,404 | 6.49 | 83.64K | 0.0018% | ||
| 03-09 | Fiscal year | Chief Executive Officer | 455,567 | 10.39 | 1.28M | 0.0224% | ||
| 03-09 | Free | Executive/Senior Manager | 19,592 | - | - | 0.0010% | ||
| 03-09 | Fiscal year | Chief Technology Officer | 91,712 | 9.30 | 273K | 0.0045% | ||
| 03-09 | Fiscal year | Chief Technology Officer | 134,049 | 9.24 | 396K | 0.0066% | ||
| 03-09 | Fiscal year | Chief Financial Officer | 255,240 | 9.31 | 969K | 0.0125% | ||
| 03-09 | Fiscal year | EVP, Corporate Affairs | 31,728 | 8.05 | 76.67K | 0.0016% | ||
| 03-09 | Free | President, RayzeBio Org. | 28,572 | - | - | 0.0014% | ||
| 03-09 | Fiscal year | Controller/Auditor | 28,756 | 8.18 | 81.66K | 0.0014% | ||
| 02-26 | Fiscal year | President, RayzeBio Org. | 8,244 | 21.03 | 104K | 0.0004% | ||
| 01-31 | Free | Director | 3,996 | - | - | 0.0002% | ||
| 01-31 | Free | Director | 3,996 | - | - | 0.0002% | ||
| 01-31 | Free | Director | 3,996 | - | - | 0.0002% | ||
| 01-31 | Free | Director | 3,996 | - | - | 0.0002% | ||
| 01-31 | Free | Director | 3,996 | - | - | 0.0002% | ||
| 01-31 | Free | Director | 3,996 | - | - | 0.0002% | ||
| 01-31 | Free | Director | 3,996 | - | - | 0.0002% | ||
| 01-31 | Fiscal year | Chief Technology Officer | 5,919 | 13.58 | 45.86K | 0.0003% | ||
| 01-31 | Free | Director | 3,996 | - | - | 0.0002% | ||
| 01-31 | Free | Director | 3,996 | - | - | 0.0002% | ||
| 01-31 | Free | Director | 3,996 | - | - | 0.0002% | ||
| 01-31 | Fiscal year | President, RayzeBio Org. | 23,968 | 15.10 | 210K | 0.0012% | ||
| 12-30 | Free | Director | 927 | - | - | 0.0000% | ||
| 12-30 | Free | Director | 695 | - | - | 0.0000% | ||
| 12-30 | Free | Director | 626 | - | - | 0.0000% | ||
| 12-30 | Free | Director | 649 | - | - | 0.0000% | ||
| 12-30 | Free | Director | 649 | - | - | 0.0000% | ||
| 11-02 | Other | Executive/Senior Manager | 22,568 | - | - | 0.0011% | ||
| 10-31 | Fiscal year | Chief Executive Officer | 7,710 | 12.02 | 57.03K | 0.0004% | ||
| 10-31 | Fiscal year | Chief Technology Officer | 15,227 | 13.72 | 123K | 0.0007% | ||
- Stock Market
- Stocks
- BMY Stock
- Company Bristol-Myers Squibb Company
- Insider transactions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















